Clinical Trial Update: A Study of Isatuximab Added to Standard CyBorD Induction and Lenalidomide Maintenance Treatments in ND-TEMM [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the addition of isatuximab to CyBorD induction and lenalidomide maintenance in newly diagnosed transplant-eligible multiple myeloma; st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bortezomib (bortezomib)
• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• DEXAMETHASONE (Dexamethasone)
• Isatuximab (isatuximab)
• Lenalidomide (lenalidomide)

Snippet

Sponsor: Canadian Myeloma Research Group | Conditions: Multiple Myeloma | Phase 2 | Status: ACTIVE_NOT_RECRUITING